Safety and Efficacy Evaluation of the Monopolar Radiofrequency Device for the Improvement of Facial Wrinkles
Safety and Efficacy Evaluation of the Monopolar Radiofrequency Device for the Improvement of the Facial Wrinkles, a Prospective, Multicenter, Evaluator Blinded, Randomized, Parallel-controlled, Non-inferior Clinical Trial
The goal of this clinical trial is to evaluate the safety and efficacy of the monopolar radiofrequency therapy device developed by CLASSYS Inc. for improving facial and periorbital wrinkles. This is a prospective, multicenter, evaluator-blinded, randomized, parallel-controlled, non-inferiority clinical trial.
The main questions the study aims to answer are:
Does the monopolar radiofrequency device improve the appearance of facial and periorbital wrinkles? Is the safety profile of the monopolar radiofrequency device acceptable?
Researchers will compare the investigational device to the Thermage CPT System (Solta Medical Co., Ltd.) to see if the monopolar radiofrequency device is non-inferior in terms of wrinkle improvement.
Participants will:
Undergo a single treatment session with either the investigational device or the control device.
Be followed up for a period of 3 months to assess wrinkle improvement and safety outcomes.
The primary outcome will be the improvement in facial and periorbital wrinkles, measured by the Facial Wrinkle and Elasticity Scale (FWES), 3 months post-treatment. Secondary outcomes include the Global Aesthetic Improvement Scale (GAIS) and a Visual Analog Scale (VAS) for pain. Safety evaluations will include adverse event (AE) and serious adverse event (SAE) monitoring.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Beijing Anzhen Hospital[北京安贞医院]
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 65 years old（The date of signing the informed consent shall prevail）, gender is not limited.
- Facial and periorbital wrinkle and elasticity Scale (FWES) Score ≥ 3 points. Both the facial and periorbital FWES should meet the criteria.
- The subject fully understands the benefits and risks of this experiment, and is still willing to participate and sign the informed consent.
Exclusion Criteria:
- Individuals with skin diseases, scars, open wounds, or metal implants in the area where clinical trial medical devices will be applied.
- Patients with implanted electrical devices (e.g., pacemakers, AICDs).
- Those with a history of hypertrophic scars, keloids, or severe allergic reactions.
- Individuals with excessive facial fat requiring surgical treatment.
- Those with autoimmune diseases, acute viral herpes, or poorly controlled diabetes.
- People with abnormal coagulation function or those taking anticoagulant medications (e.g., aspirin, warfarin) within 1 week of screening.
- Individuals treated with fillers or botulinum toxin within the last 6 months or permanent fillers in the treatment area.
- Those who have received skin treatments (e.g., deep exfoliation, lasers, light therapy) in the treatment area within 6 months.
- Pregnant or lactating women, or women of childbearing potential not using medically accepted contraception.
- Persons deemed inappropriate by the investigator to participate in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: VOLNEWMER
A non-invasive skin tightening treatment using the Volnewmer device.
|
Non-invasive radiofrequency-based skin tightening using the Volnewmer device.
|
|
Active Comparator: Thermage CPT
A non-invasive skin tightening treatment using the Thermage CPT device.
|
Non-invasive radiofrequency-based skin tightening using the Thermage CPT device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FWES
Time Frame: 3 months after the treatment
|
Facial wrinkle improvement was defined as reduction of FWES subgroup score≥1.
|
3 months after the treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: 文志 李, Beijing Anzhen Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLSSPZLY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.